Phase 2 Breast Cancer Trial, Not Yet Recruiting NCT06339281 Sponsor: Li Huiping Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Not Yet Recruiting

NCT06339281
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People with breast cancer that has been confirmed by lab testing to be HER-2 negative and hormone receptor (HR) positive, and whose cancer has continued to grow or spread, and who have previously received chemotherapy containing anthracycline and/or paclitaxel (either before or after surgery, or for advanced disease).
  • People who have received no more than 3 rounds of chemotherapy for cancer that has come back or spread to other parts of the body.
  • People whose cancer has previously continued to grow while being treated with hormone therapy and a type of targeted therapy called CDK4/6 inhibitors, for cancer that has come back or spread.
  • People whose PET-CT scan shows a specific level of cancer activity (SUV greater than 5) (confirm with trial site).
  • People aged 18 years or older.
  • People who are considered reasonably active and able to care for themselves, based on a standard medical performance scale (ECOG score of 0 or 1).
  • People with a life expectancy of at least 3 months.
  • People who have at least one measurable area of cancer that can be tracked on a CT or MRI scan, following specific measurement guidelines, and where that area has not been surgically removed, has not received radiotherapy, or has come back in an area that was previously treated with radiotherapy.
  • People with adequate blood cell counts (confirm with trial site).
  • People with adequate liver function (confirm with trial site).
  • People with adequate kidney function (confirm with trial site).
  • People with normal blood clotting function.
  • Women who are able to become pregnant and are willing to use contraception throughout the trial, and who have had a negative pregnancy test within 7 days before starting treatment.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have received radiation therapy within the 28 days before enrolling, unless it was a limited course of radiotherapy to relieve bone pain from cancer spread, affecting no more than 30% of the body's bone marrow-containing bones (confirm with trial site).
  • People who have cancer that has spread to the brain or central nervous system.
  • People who are currently taking another experimental drug or are participating in another clinical trial, or who have done so within the 30 days before enrolling.
  • People who have had another type of cancer within the past 5 years, with the exception of certain skin cancers or early-stage cervical cancer that have been adequately treated.
  • People with high blood pressure that remains uncontrolled despite medication (systolic pressure of 140 mmHg or higher, or diastolic pressure of 90 mmHg or higher).
  • People with significant heart conditions, including moderate-to-severe reduced blood supply to the heart, a past heart attack, or poorly controlled irregular heart rhythms (including certain abnormal readings on a heart electrical test).
  • People with severe heart failure, or whose heart pumping function (measured as left ventricular ejection fraction) is below 50% on an ultrasound.
  • People with abnormal blood clotting results, a tendency to bleed, or who are currently receiving blood-thinning or clot-dissolving treatment.
  • People who have had significant bleeding in the past 3 months, such as bleeding in the digestive system, a bleeding stomach ulcer, a high level of hidden blood in the stool, or inflammation of blood vessels.
  • People who have had major surgery, a serious injury, a bone fracture, or an open wound in the past 4 weeks.
  • People who have difficulty absorbing oral medications, for example due to an inability to swallow, ongoing severe diarrhoea, or a bowel blockage.
  • People whose urine tests show significant levels of protein, or whose 24-hour urine protein measurement is 1.0 g or more.
  • People who have a build-up of fluid (such as in the chest, abdomen, or around the heart) that is causing symptoms and requires a medical procedure to drain.
  • People who, in the opinion of the trial doctor, have other conditions that could affect how the trial is conducted or how the results are interpreted.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 July 2026

Contact this trial

Principal Investigator: Huiping Li, MD, Peking University Cancer Hospital & Institute

Phone: (0086)13811012595

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Li Huiping
Registry
ClinicalTrials.gov
Start date
1 May 2024
Est. completion
1 June 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Primary endpoints

Progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov